Innate Pharma SA (IPHA) community

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30

$1.38−0.11 (-7.38%)

Close on Nov 13, 2026Market cap $129.33MP/E –Yield –

Community

Notes and questions about Innate Pharma from other investors

No posts about IPHA yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Innate Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPHA.

Compare: IPHA vs MOLN · IPHA vs TCRX · IPHA vs EVAX · IPHA vs CRBU · IPHA vs CRIS

Revenue growth-55.2% · median -18.4%

Operating margin-599.8% · median -1693.7%

Company	Revenue	Growth
CRBU	$9.44M	+1.6%
IPHA	€9.01M	-55.2%
TCRX	$5.19M	-38.4%
MOLN	–	–
EVAX	–	–
CRIS	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 181
Auditor: Deloitte & Associes
SEC CIK: 1598599

Advertisement
300 × 250

See a number that looks wrong?